Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.38 |
| ▸ | GAA | P10253 | 4/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | PANK3 | Q9H999 | 3/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.33 |
| ▸ | CXCL8 | P10145 | 2/20 | 0.33 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.33 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.33 |
| ▸ | ALB | P02768 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | RARB | P10826 | 1/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5954013 | 0.98 | LMNA (0.50) | LMNAKMT2AALDH1A1GAAPTGS2 | |
| SCHEMBL2713827 | 0.81 | LMNA (0.49) | LMNAKMT2AALDH1A1GAAL3MBTL1 | |
| Lithium Ion SCHEMBL247636 | 0.80 | LMNA (0.47) | LMNAKMT2AALDH1A1GAAL3MBTL1 | |
| Lithium Ion SCHEMBL31014510 | 0.80 | LMNA (0.47) | LMNAKMT2AALDH1A1GAAL3MBTL1 | |
| SCHEMBL11868268 | 0.77 | LMNA (0.47) | LMNAKMT2AALDH1A1GAAL3MBTL1 | |
| SCHEMBL9260962 | 0.75 | LMNA (0.46) | LMNAKMT2AALDH1A1GAAL3MBTL1 | |
| SCHEMBL31015530 | 0.74 | LMNA (0.47) | LMNAKMT2AALDH1A1GAAL3MBTL1 | |
| SCHEMBL2600116 | 0.73 | ALDH1A1 (0.46) | LMNAKMT2AALDH1A1GAAL3MBTL1 | |
| SCHEMBL7586507 | 0.71 | GAA (0.45) | LMNAKMT2AALDH1A1GAAL3MBTL1 | |
| SCHEMBL31405028 | 0.71 | ALDH1A1 (0.44) | LMNAKMT2AALDH1A1GAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250002475-A1 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | EPICS THERAPEUTICS (BE) | 2025-01-02 | — | — | US | disclosed |
| US-12091400-B2 | Piperidine derivatives as METTL3 inhibitors | EPICS THERAPEUTICS (BE) | 2024-09-17 | — | — | US | disclosed |
| US-20240270716-A1 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | EPICS THERAPEUTICS (BE) | 2024-08-15 | — | — | US | disclosed |
| EP-2313407-B1 | cMET INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2016-10-05 | — | — | EP | disclosed |
| CN-102124005-B | Cmet inhibitors | TAKEDA PHARMACEUTICAL | 2014-06-04 | — | — | CN | disclosed |
| US-20130315895-A1 | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-28 | — | — | US | disclosed |
| EP-2588107-A1 | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET | Takeda Pharmaceutical Company Limited (JP) | 2013-05-08 | — | — | EP | disclosed |
| US-8178534-B2 | cMET inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-15 | — | — | US | disclosed |
| WO-2012003338-A1 | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-01-05 | — | — | WO | disclosed |
| CN-102124005-A | Cmet inhibitors | TAKEDA PHARMACEUTICAL | 2011-07-13 | — | — | CN | disclosed |
| EP-2313407-A1 | cMET INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2011-04-27 | — | — | EP | disclosed |
| US-20100063054-A1 | cMET INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-11 | — | — | US | disclosed |
| WO-2010019899-A1 | cMET INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130315895-A1 | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET | HGF, MET, HGFAC | LMNA 4523/4885KMT2A 233/4885ALDH1A1 3001/4885 |
| US-20240270716-A1 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | METTL3, METTL16, DIMT1 | LMNA 3137/4885KMT2A 208/4885ALDH1A1 205/4885 |
| US-20100063054-A1 | cMET INHIBITORS | CEPT1, LCAT, GNMT | LMNA 3512/4885KMT2A 394/4885ALDH1A1 3166/4885 |
| US-20250002475-A1 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | METTL3, METTL16, DIMT1 | LMNA 3137/4885KMT2A 208/4885ALDH1A1 205/4885 |
| US-12091400-B2 | Piperidine derivatives as METTL3 inhibitors | METTL3, METTL16, DIMT1 | LMNA 3137/4885KMT2A 208/4885ALDH1A1 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.